Revenue growth of ~20% in FY27
Management expects ~20% revenue growth on standalone basis for FY27, driven by volume and new capacities.
PRIVISPECIALITYCHEMICALS / guidance tracker
Keep management guidance in view.
Privi Speciality Chemicals · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
EBITDA margin to sustain above 25%
Management guided for 25%+ EBITDA margins going forward, supported by operational efficiencies and product mix.
Phase 1 capacity expansion to 54,000 MT by June 2026
First phase of capex to increase total installed capacity to 54,000 MT per annum by June 2026.
New specialty products (maltol, cyclopentanone) commercial by Q1 FY27
Maltol, ethyl maltol, and cyclopentanone projects to achieve mechanical completion by June 2026, with commercial production soon after.